Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
REPROCELL INCORPORATED |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 209.00 JPY | -0.48% | -1.88% | -31.02% | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2024 * | 2,770 M 18.87 M | Sales 2025 * | 3,320 M 22.62 M | Capitalization | 17.87 B 122 M |
|---|---|---|---|---|---|
| Net income 2024 * | -80.00 M -544,960 | Net income 2025 * | 10.00 M 68,120 | EV / Sales 2024 * | 4,19x |
| Net cash position 2024 * | 6,259 M 42.64 M | Net cash position 2025 * | 6,149 M 41.89 M | EV / Sales 2025 * | 3,53x |
| P/E ratio 2024 * | -223x | P/E ratio 2025 * | 1 750x | Employees | 92 |
| Yield 2024 * | - | Yield 2025 * | - | Free-Float | 93.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.41% | ||
| Current month | -9.09% | ||
| 1 month | -7.08% | ||
| 3 months | -18.29% | ||
| 6 months | -22.79% | ||
| Current year | -30.69% |
1 week
209.00
220.00
1 month
208.00247.00
Current year
208.00329.00
1 year
208.00380.00
3 years
187.00458.00
5 years
170.00547.00
10 years
170.002 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shigetomo Akano
DFI | Director of Finance/CFO | 41 | 2020 |
| President | 55 | 2004 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 2015 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2008 | |
| President | 55 | 2004 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 2015 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 589 M€ | +2.35% | - | |
| 0.01% | 14,684 M€ | +9.53% | - | |
| 0.00% | 204 M€ | +5.90% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-29 | 209.00 | -0.48% | 551 900 |
| 23-11-28 | 210.00 | -0.47% | 550,600 |
| 23-11-27 | 211.00 | -2.76% | 470,700 |
| 23-11-24 | 217.00 | +1.88% | 478,000 |
| 23-11-22 | 213.00 | -0.93% | 266,000 |
Delayed Quote Japan Exchange, November 28, 2023 at 08:36 pm EST
More quotes
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
Sector
Pharmaceuticals
Calendar
2024-02-08
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -30.69% | 121 M $ | |
| -9.05% | 81 646 M $ | |
| -11.45% | 38 459 M $ | |
| -17.88% | 33 151 M $ | |
| -23.31% | 25 148 M $ | |
| +15.19% | 22 868 M $ | |
| -15.16% | 16 689 M $ | |
| -7.88% | 14 304 M $ | |
| -34.39% | 11 849 M $ | |
| +35.67% | 9 398 M $ |